Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded down 19.4% on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares traded hands during trading, a decline of 1% from the average session volume of 525,193 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The firm has a market capitalization of C$21.13 million, a P/E ratio of -4.23 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The business’s 50 day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
